These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26731899)

  • 1. [Alternative Splicing Detection as a Biomarker for Cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate].
    Kitamura K; Matsushita K; Kobayashi S; Ishige T; Semba T; Kimura A; Kazami T; Ohyama M; Itoga S; Beppu M; Nishimura M; Satoh M; Nomura F
    Rinsho Byori; 2015 Sep; 63(9):1091-102. PubMed ID: 26731899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
    Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
    Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.
    Matsushita K; Kajiwara T; Tamura M; Satoh M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Yoshimoto R; Ito A; Kubo S; Natsume T; Levens D; Yoshida M; Nomura F
    Mol Cancer Res; 2012 Jun; 10(6):787-99. PubMed ID: 22496461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alternative Splicing Detection as Biomarker Candidates for Cancer Diagnosis and Treatment with Establishment of Clinical Biobank in Chiba University].
    Matsushita K; Itoga S; Nishimura M; Furuta K; Nomura F
    Rinsho Byori; 2015 Mar; 63(3):347-60. PubMed ID: 26524858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues.
    Kajiwara T; Matsushita K; Itoga S; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Habara Y; Matsuo M; Nomura F
    Cancer Sci; 2013 Feb; 104(2):149-56. PubMed ID: 23113893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
    Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
    Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
    Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
    Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.
    Ogura Y; Hoshino T; Tanaka N; Ailiken G; Kobayashi S; Kitamura K; Rahmutulla B; Kano M; Murakami K; Akutsu Y; Nomura F; Itoga S; Matsubara H; Matsushita K
    Oncotarget; 2018 May; 9(33):22929-22944. PubMed ID: 29796163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancer.
    Ailiken G; Kitamura K; Hoshino T; Satoh M; Tanaka N; Minamoto T; Rahmutulla B; Kobayashi S; Kano M; Tanaka T; Kaneda A; Nomura F; Matsubara H; Matsushita K
    Oncogenesis; 2020 Feb; 9(2):26. PubMed ID: 32071290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Link of mRNA and rRNA Transcription by PUF60/FIR through TFIIH/P62 as a Novel Therapeutic Target for Cancer.
    Kitamura K; Hoshino T; Okabe A; Fukuyo M; Rahmutulla B; Tanaka N; Kobayashi S; Tanaka T; Shida T; Ueda M; Minamoto T; Matsubara H; Kaneda A; Ishii H; Matsushita K
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
    Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
    World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kimura A; Kitamura K; Ailiken G; Satoh M; Minamoto T; Tanaka N; Nomura F; Matsushita K
    Oncotarget; 2017 Sep; 8(40):67955-67965. PubMed ID: 28978087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
    Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
    Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.
    Kobayashi S; Hiwasa T; Ishige T; Rahmutulla B; Kano M; Hoshino T; Minamoto T; Shimada H; Nomura F; Matsubara H; Matsushita K
    Cancer Sci; 2019 Jun; 110(6):2004-2013. PubMed ID: 30980774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
    Kobayashi S; Hoshino T; Hiwasa T; Satoh M; Rahmutulla B; Tsuchida S; Komukai Y; Tanaka T; Matsubara H; Shimada H; Nomura F; Matsushita K
    Oncotarget; 2016 Dec; 7(50):82493-82503. PubMed ID: 27756887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis.
    Matsushita K; Tomonaga T; Shimada H; Shioya A; Higashi M; Matsubara H; Harigaya K; Nomura F; Libutti D; Levens D; Ochiai T
    Cancer Res; 2006 Feb; 66(3):1409-17. PubMed ID: 16452196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment].
    Matsushita K; Kajiwara T; Itoga S; Satoh M; Sogawa K; Umemura H; Sawai S; Nishimura M; Tamura M; Tanaka N; Shimada H; Tomonaga T; Nomura F
    Rinsho Byori; 2009 Dec; 57(12):1151-8. PubMed ID: 20077813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.
    Hahn CN; Venugopal P; Scott HS; Hiwase DK
    Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.
    Darman RB; Seiler M; Agrawal AA; Lim KH; Peng S; Aird D; Bailey SL; Bhavsar EB; Chan B; Colla S; Corson L; Feala J; Fekkes P; Ichikawa K; Keaney GF; Lee L; Kumar P; Kunii K; MacKenzie C; Matijevic M; Mizui Y; Myint K; Park ES; Puyang X; Selvaraj A; Thomas MP; Tsai J; Wang JY; Warmuth M; Yang H; Zhu P; Garcia-Manero G; Furman RR; Yu L; Smith PG; Buonamici S
    Cell Rep; 2015 Nov; 13(5):1033-45. PubMed ID: 26565915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.